Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 192Breast 111Other hematologic neoplasm 58Sarcoma 48Genitourinary 20Plasma cell 16Gynecologic 16CNS 16Gastrointestinal 15Endocrine 6Tumor-Agnostic 5Thoracic 4Myeloid 3Head & Neck 3Other solid neoplasm 2NET 2Dermatologic 2Other 1Classical hematology 1

Conditions

Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Doxorubicin × Tumor-Agnostic × Clear all
NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

NCT02377752 2021-02-17

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
25 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT02677116 2020-05-20

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Eli Lilly and Company

Phase 1 Completed
68 enrolled 26 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00305084 2019-10-04

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

AGC Biologics S.p.A.

Phase 1 Completed
15 enrolled 20 charts
Tumor-Agnostic

Neoplasms

NCT01031420 2019-09-17

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

Phase 2 Completed
54 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡